September 4, 2024 07:36 AM EDTUpdated September 6, 11:35 PM
R&D
Pharma

Roche un­veils more mid-stage da­ta for BTK in­hibitor in re­laps­ing mul­ti­ple scle­ro­sis

Katherine Lewin

News Reporter

Roche tout­ed new Phase 2 da­ta for its BTK in­hibitor fene­bru­ti­nib in re­laps­ing mul­ti­ple scle­ro­sis, not­ing that pa­tients on the drug main­tained low lev­els of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times